Natixis Advisors’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-212,138
| Closed | -$1.88M | – | 1668 |
|
|
2025
Q1 | $1.88M | Buy |
212,138
+2,810
| +1% | +$33.7K | ﹤0.01% | 1104 |
|
|
2024
Q4 | $2.87M | Sell |
209,328
-110,685
| -35% | -$2.04M | 0.01% | 995 |
|
|
2024
Q3 | $8.77M | Buy |
320,013
+44,646
| +16% | +$1.21M | 0.02% | 691 |
|
|
2024
Q2 | $6.74M | Buy |
275,367
+37,002
| +16% | +$812K | 0.01% | 720 |
|
|
2024
Q1 | $5.08M | Buy |
238,365
+48,087
| +25% | +$1.03M | 0.01% | 789 |
|
|
2023
Q4 | $3.64M | Buy |
190,278
+58,449
| +44% | +$1.01M | 0.01% | 846 |
|
|
2023
Q3 | $2.12M | Sell |
131,829
-6,695
| -5% | -$127K | 0.01% | 968 |
|
|
2023
Q2 | $3.21M | Buy |
138,524
+29,645
| +27% | +$647K | 0.01% | 841 |
|
|
2023
Q1 | $2.53M | Buy |
108,879
+50,773
| +87% | +$1.03M | 0.01% | 882 |
|
|
2022
Q4 | $843K | Buy |
58,106
+5,538
| +11% | +$103K | ﹤0.01% | 1187 |
|
|
2022
Q3 | $1M | Buy |
52,568
+34,873
| +197% | +$800K | ﹤0.01% | 1109 |
|
|
2022
Q2 | $322K | Buy |
17,695
+2,938
| +20% | +$61K | ﹤0.01% | 1361 |
|
|
2022
Q1 | $372K | Buy |
+14,757
| New | +$378K | ﹤0.01% | 1337 |
|
|
2017
Q3 | – | Sell |
-109,275
| Closed | -$2.82M | – | 1044 |
|
|
2017
Q2 | $2.82M | Buy |
109,275
+14,375
| +15% | +$305K | 0.03% | 614 |
|
|
2017
Q1 | $1.82M | Buy |
94,900
+6,202
| +7% | +$110K | 0.02% | 725 |
|
|
2016
Q4 | $1.48M | Sell |
88,698
-2,145
| -2% | -$38.8K | 0.02% | 746 |
|
|
2016
Q3 | $1.87M | Buy |
90,843
+6,272
| +7% | +$159K | 0.02% | 665 |
|
|
2016
Q2 | $2.59M | Buy |
84,571
+19,779
| +31% | +$687K | 0.04% | 566 |
|
|
2016
Q1 | $2.42M | Buy |
64,792
+38,658
| +148% | +$1.46M | 0.04% | 569 |
|
|
2015
Q4 | $1.13M | Buy |
26,134
+7,966
| +44% | +$337K | 0.02% | 748 |
|
|
2015
Q3 | $681K | Buy |
18,168
+2,002
| +12% | +$71.1K | 0.01% | 848 |
|
|
2015
Q2 | $549K | Buy |
16,166
+217
| +1% | +$7.38K | 0.01% | 891 |
|
|
2015
Q1 | $565K | Buy |
15,949
+1,743
| +12% | +$62.4K | 0.01% | 893 |
|
|
2014
Q4 | $484K | Buy |
14,206
+180
| +1% | +$6.39K | 0.01% | 927 |
|
|
2014
Q3 | $541K | Buy |
14,026
+1,506
| +12% | +$56.2K | 0.01% | 894 |
|
|
2014
Q2 | $487K | Sell |
12,520
-2,686
| -18% | -$99.9K | 0.01% | 1005 |
|
|
2014
Q1 | $520K | Sell |
15,206
-43,738
| -74% | -$1.36M | 0.01% | 937 |
|
|
2013
Q4 | $1.24M | Buy |
58,944
+10,606
| +22% | +$268K | 0.02% | 680 |
|
|
2013
Q3 | $1.14M | Buy |
48,338
+4,910
| +11% | +$139K | 0.02% | 654 |
|
|
2013
Q2 | $1.17M | Buy |
+43,428
| New | +$1.26M | 0.02% | 644 |
|
Other funds holding MYGN
GCM
Natixis Advisors's MYGN Position: Q2 2025 in Review
Natixis Advisors sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 212,138 shares — an estimated $1.88M sold.
Natixis Advisors first reported a position in MYGN in Q2 2013 and held it in 30 quarters. The position peaked at $8.77M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.
- Natixis Advisors reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
- Natixis Advisors sold 212,138 Myriad Genetics shares in Q2 2025, an estimated $1.88M.
- Natixis Advisors first reported a position in Myriad Genetics in Q2 2013 and held it in 30 quarters.
- Natixis Advisors's Myriad Genetics position peaked at $8.77M in Q3 2024.
- 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.
Based on Natixis Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.